Credit Suisse Ag Biomarin Pharmaceutical Inc Put Options Transaction History

Credit Suisse Ag

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2021 Feb 14, 2022	SELL	$71.72 - $91.47 $8.47 Million - $10.8 Million	-118,100 Reduced 72.32%	45,200 $3.99 Million
Q3 2021 Nov 12, 2021	SELL	$74.77 - $85.47 $5.97 Million - $6.83 Million	-79,900 Reduced 32.85%	163,300 $12.6 Million
Q2 2021 Aug 16, 2021	SELL	$75.51 - $84.79 $2.42 Million - $2.71 Million	-32,000 Reduced 11.63%	243,200 $20.3 Million
Q1 2021 May 14, 2021	BUY	$74.73 - $90.69 $5.33 Million - $6.47 Million	71,300 Added 34.97%	275,200 $20.8 Million
Q4 2020 Feb 12, 2021	BUY	$72.61 - $90.2 $12.7 Million - $15.8 Million	174,700 Added 598.29%	203,900 $17.9 Million
Q3 2020 Nov 13, 2020	BUY	$71.87 - $131.03 $1.38 Million - $2.52 Million	19,200 Added 192.0%	29,200 $2.22 Million
Q1 2019 May 14, 2019	SELL	$84.2 - $98.62 $2.19 Million - $2.56 Million	-26,000 Reduced 72.22%	10,000 $888,000
Q3 2018 Nov 13, 2018	SELL	$93.92 - $105.72 $2.82 Million - $3.17 Million	-30,000 Reduced 45.45%	36,000 $3.49 Million
Q1 2018 May 15, 2018	BUY	$77.67 - $92.63 $2.33 Million - $2.78 Million	30,000 Added 83.33%	66,000 $5.35 Million
Q4 2017 Feb 14, 2018	BUY	$80.76 - $95.13 $2.91 Million - $3.42 Million	36,000	36,000 $3.21 Million

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.